Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation

Name: Kaimen Rigor review — Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation
Item: Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation
Rating: 54
Author: Alpha1

Mohamad EA, Aly AA, Khalaf AA, Ahmed MI, Kamel RM, Abdelnaby SM, Abdelzaher YH, Sedrak MG, Mousa SA.

Paper source

Read full text (PMC)Journal

Embed this Rigor badge

Kaimen Rigor review — 1★ (Critical), 0 critical, 9 high issues for “Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 5, 2026

Read alongside

Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation

Mohamad EA, Aly AA, Khalaf AA, Ahmed MI, Kamel RM, Abdelnaby SM, Abdelzaher YH, Sedrak MG, Mousa SA.

Read full text (PMC)

Journal

DOI

10.2147/dddt.s316247

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/245ce65c-8e4a-4f57-a343-2b9b2822d30d" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/245ce65c-8e4a-4f57-a343-2b9b2822d30d/badge" alt="Kaimen Rigor review — 1★ (Critical), 0 critical, 9 high issues for “Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

c4730f21983ec5e99b4f2046116b612097bc6ac8407175f8ad0209ae9847025a

Verify via API

Issued Aug 5, 2026Engine 7.15.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation

Mohamad EA, Aly AA, Khalaf AA, Ahmed MI, Kamel RM, Abdelnaby SM, Abdelzaher YH, Sedrak MG, Mousa SA.

Paper source

Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation

Read full text (PMC)Journal

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 5, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×5−2.5★
ClaimsUnsupported claim (uncorroborated)−0.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design not met−0.5★
ReportingKey resources not met−0.5★
ReportingData & code availability not met−0.5★
ReportingStatistical analysis partially met−0.25★
ReportingReporting transparency partially met−0.25★
CitationsRetracted reference cited−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: moderateReviewer agreement: moderateEngine: 7.15.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.
No data or code availability links were detected to verify.

Biggest issues

01Conclusion not supported by the paper’s own evidence
highOverreachreviewer-assessedFull detail
Punicalagin increased human TERT concentration in skin cells.
telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s + H2O2 samples by only 31.19% and 6.5%, respectively
Resultsreviewer’s wording
02Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim rests on in vitro cell-based biomarkers (gene expression changes in MMP3, Col1A1, Timp3, TERT concentration, cell cycle arrest, and collagen level). The paper does not demonstrate target engagement at the tested dose (no PK/PD or dose–exposure relationship for the cellular effect) and does not cite validated evidence linking these surrogates to a clinical outcome in skin aging.
“Punicalagin succeeded in reducing the growth arrest of HFB4 cells, activated production of the Col1A1 and Timp3 genes, maintained collagen level, and lowered MMP3. Punicalagin increased human TERT concentration in skin cells.”
03Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes (e.g., percentage telomere shortening: 64.20% vs 31.19% for H2O2, 14.22% vs 6.5% for UV) are presented without any anchor to a clinically or biologically meaningful threshold. No minimal clinically important difference or reference to physiological relevance is provided.
“telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s+H2O2 samples by only 31.19% and 6.5%”
04Study design lacks key rigor safeguards
highDisclosurereviewer-assessedFull detail
The study design lacks essential rigor elements: no randomization, blinding, power analysis, proper replication, or outlier handling. Only basic controls are present.
05Key resources not identified
highDisclosurereviewer-assessedFull detail
Key resources are poorly identified: cell line authentication and mycoplasma testing are absent, and most reagents lack catalog numbers. Only statistical software is adequately identified.
“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt”
Methods
06Data and code not shared
highDisclosurereviewer-assessedFull detail
No data availability statement, data deposit, accession numbers, or code sharing are provided.

6 further findings of this severity or below — every one is in the sections below, filed under its error type.

Findings by category

101ArithmeticNumerical inconsistencies 502OverreachOverstated conclusions 103AuthenticityData authenticity concerns 504DisclosureReporting gaps 205AvailabilityBroken references and links · partly checked 106CopyeditCopyediting

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper presents a clear rationale for using punicalagin-loaded niosomes as an anti-aging agent, but the study design lacks essential rigor elements (no randomization, blinding, power analysis, replicate distinction) and statistical reporting is incomplete. Key resources are poorly identified, data are not publicly available, and internal contradictions in the reported niosome sizes and TERT assay results undermine the conclusions.

This evaluation synthesizes three independent reviewer runs. The paper is an in vitro cell line study; biological variables and ethical approvals were deemed not applicable. The statistics verification component checked 0 tests, so no mathematical verification was performed. The citation check identified one retracted and one potentially fabricated reference.

Numerical inconsistencies

1 finding · worst medium

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions

5 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions not supported by the paper’s own evidenceAssessed
Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst medium

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Methods and results do not matchAssessed

5 integrity concerns flagged (1 high).

Reporting gaps

5 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Key resources not identifiedAssessed
Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Study design lacks key rigor safeguardsAssessed
Reporting/transparency gapsAssessed

Eight Dimensions2 pass · 2 warn · 3 fail

The introduction cites numerous studies on skin aging mechanisms, UV damage, ROS, and the antioxidant potential of pomegranate extracts. It establishes a clear premise that punicalagin, a polyphenol, can counteract oxidative stress and photoaging. However, limitations of prior research are not explicitly addressed, and the rationale is somewhat generic.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedNOT REPORTED

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

The paper adequately cites prior work and establishes a logical rationale, but limitations of the study are only briefly mentioned.

Evidence

paraphrase[Introduction, paragraphs 1-6]

“Paraphrase: The introduction cites multiple references on skin aging, ROS, UV, pomegranate composition, and niosomes.”

“In this study, we extracted punicalagin from pomegranate peel and then encapsulated it in niosomes to treat the HFB4 cell line as an anti-aging agent.”

Introduction

“Because of complexity of skin aging, future studies are required to use human skin and in vivo swine skin model of UV-mediated skin damage and aging to define the efficacy of punicalagin niosomes in skin aging.”

Discussion

PASSReviewer 2· 90% conf

The paper adequately cites prior research on skin aging, ROS, and pomegranate compounds, and provides a logical rationale linking punicalagin's antioxidant properties to anti-aging effects.

Evidence

paraphrase[Introduction, paragraph 7]

“Previous studies showed that treating human skin fibroblasts with 0–500 µM H2O2 decreased the viability of cells in a concentration-dependent manner.”

“The natural antioxidants from plant secondary metabolites can protect human skin from photoaging.”

Introduction ¶9

absence[Introduction]

Limitations of prior research are not discussed.

WARNReviewer 3· 70% conf

The paper establishes a scientific premise by citing prior work on skin aging and antioxidants, but does not critically evaluate the strengths and weaknesses of prior research or address limitations of previous studies.

Evidence

paraphrase[Introduction, paragraphs 1-5]

“The introduction cites multiple references on skin aging, ROS, collagen, MMPs, TIMPs, telomerase, antioxidants, and pomegranate.”

absence[Introduction]

Strengths and weaknesses of prior work are not acknowledged.

absence[Introduction]

Limitations of prior research are not addressed.

The paper describes an in vitro study with five groups (untreated, H2O2, UV, punicalagin+H2O2, punicalagin+UV) but does not mention randomization of cell cultures to groups, blinding of the investigator, or a priori sample size calculation. Distinction between biological and technical replicates is not made, and no outlier handling is reported. The only adequate element is the presence of appropriate controls (untreated cells, H2O2-only, UV-only).

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsNOT REPORTED

outlier handlingNOT REPORTED

randomization unitNOT REPORTED

inclusion exclusionNOT REPORTED

randomization methodNOT REPORTED

replicate distinctionNOT REPORTED

independent replicationNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 90% conf

The study lacks essential design elements such as randomization, blinding, power analysis, and replication, with only controls adequately reported.

Evidence

paraphrase[Methods, Effect of H2O2 and Punicalagin on HFB4]

“The cells then were distributed into three groups in T-75 flasks: untreated cells (CC), cells treated with concentration (0.11 mM) of H2O2 (H2O2/HFB4), and cells treated with punicalagin (0.27 Mm) in addition to hydrogen peroxide (0.11 mM) (s + H2O2). Another two groups of cells were placed in 6-well plates: untreated cells + exposing to UV (cR), and cells treated with concentration (0.27Mm) of punicalagin + exposing to UV (s.R).”

absence[Methods, entire section]

No randomization or blinding is mentioned.

absence[Methods, Statistical Analysis]

No power analysis or sample size calculation is reported.

FAILReviewer 2· 95% conf

The study design lacks essential rigor elements: no randomization, blinding, power analysis, proper replication, or outlier handling. Only basic controls are present.

Evidence

paraphrase[Methods, 'Effect of H2O2 and Punicalagin on HFB4']

“untreated cells (CC), cells treated with concentration (0.11 mM) of H2O2 (H2O2/HFB4), and cells treated with punicalagin (0.27 Mm) in addition to hydrogen peroxide (0.11 mM) (s + H2O2).”

absence[Methods]

No randomization or blinding is mentioned.

absence[Methods]

No a priori power analysis is reported.

FAILReviewer 3· 80% conf

The study design lacks essential rigor elements: no power analysis, no distinction between biological and technical replicates, no outlier handling, and no independent replication. Only controls are adequately described.

Evidence

absence[Methods]

No power analysis reported.

absence[Methods, Cell Culture and Assays]

Biological vs technical replicates not distinguished.

paraphrase[Methods, Effect of H2O2 and Punicalagin on HFB4]

The study uses HFB4 human fibroblast cells, a cell line. The biological variables criteria (sex, age, weight, housing, demographics) are not relevant for cell line work. The species/strain/source is reported (human fibroblast cell line from VACSERA), but authentication is not provided. With only one applicable criterion (species_strain_source) and it being reported_but_inadequate, the dimension is not_applicable per the scoring rule (<2 applicable).

Sub-criteria

demographicsN/A

sex reportedN/A

sex justifiedN/A

age weight healthN/A

housing conditionsN/A

species strain sourceINADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The study uses a commercially available human cell line, and the reporting of biological variables is not applicable since the criteria are designed for animal or human subjects.

Evidence

paraphrase[Methods, Materials]

“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt.”

absence[Methods, Materials]

No RRID or authentication details are provided.

N/AReviewer 2· 90% conf

The study uses a human fibroblast cell line (HFB4), not animals or human subjects, so biological variables such as sex, age, and housing conditions are not applicable.

Evidence

“HFB4 (human dermal fibroblast) cell lines were preserved as a culture of monolayer in Dulbecco′s Modified Eagle′s Medium”

Methods

PASSReviewer 3· 90% conf

The only applicable biological variable, the cell line species/strain, is adequately reported. Other variables are not applicable for an in vitro cell line study.

Evidence

paraphrase[Methods, Materials]

“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt.”

The paper includes a generic 'Compliance with Ethical Standards' statement but no named IRB or IACUC. Since the work involves only a commercially available cell line and no non-public subject-level data, ethics approval is genuinely not applicable.

Sub-criteria

iacuc statementN/A

informed consentN/A

irb ethics statementN/A

regulatory complianceN/A

Per reviewer (3) — the votes behind the verdict

N/AReviewer 1· 95% conf

The study uses a commercially available cell line and does not involve human subjects or animals, so ethics approval is not required.

Evidence

“The study was conducted in accordance with the international guidelines.”

End of paper, Compliance with Ethical S…

N/AReviewer 2· 95% conf

The study involves only a commercial cell line and no human or animal subjects, so ethical approval is not required.

Evidence

“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt”

Methods

N/AReviewer 3· 95% conf

The study uses a commercially available human cell line and does not involve animal or human subjects, so ethics approval is not required.

Evidence

“The study was conducted in accordance with the international guidelines.”

Compliance with Ethical Standards

The cell line HFB4 is identified by source but not authenticated (e.g., STR profiling). Mycoplasma testing is not reported. Many reagents (e.g., FBS, antibiotics) are listed with vendor but no catalog numbers. The investigational product (punicalagin) is identified by reference standard vendor but the extracted punicalagin is not fully characterized. Software SPSS v.15.0 is adequately identified. Of 4 applicable sub-criteria (cell_line_authentication, mycoplasma_testing, reagents_identified, software_tools_identified), only software_tools_identified is adequate.

Sub-criteria

mycoplasma testingNOT REPORTED

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationNOT REPORTED

software tools identifiedADEQUATE

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 85% conf

Key resources such as cell line authentication, mycoplasma testing, and full reagent catalog numbers are not reported, while software is identified but inadequately.

Evidence

absence[Methods, Materials]

Cell line authentication not reported.

absence[Methods, all sections]

Mycoplasma testing not reported.

“Methanol, ethanol, and Tween 80 were supplied from Sigma-Aldrich Co. (Schnelldorf, Germany).”

Methods

FAILReviewer 2· 90% conf

Key resources are poorly identified: cell line authentication and mycoplasma testing are absent, and most reagents lack catalog numbers. Only statistical software is adequately identified.

Evidence

“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt”

Methods

absence[Methods]

Mycoplasma testing is not reported.

“Fetal bovine serum (FBS) was purchased from Invitrogen Corp. (Carlsbad, CA, USA). Penicillin-streptomycin, trypsin, EDTA, and Hank’s buffer were purchased from Gibco, New York, NY, USA.”

Methods

FAILReviewer 3· 80% conf

Key resources are inadequately identified: cell line authentication, mycoplasma testing, and reagent catalog numbers are not reported. Only software is adequately identified.

Evidence

absence[Methods, Materials]

Cell line authentication not reported.

absence[Methods]

Mycoplasma testing not reported.

“Tween 80 were supplied from Sigma-Aldrich Co. (Schnelldorf, Germany).”

Methods

The paper states 'one-way ANOVA analysis' for group comparisons and uses SPSS v.15.0. However, no verification of ANOVA assumptions (normality, equal variance) is reported. Exact p-values are not provided; only 'p ≤ 0.05 was considered significant'. Effect sizes and confidence intervals are not reported. Data are presented as bar charts with error bars labeled as standard deviation, but individual data points are not shown. Of 4 applicable sub-criteria, 2 (tests_named, software_identified) are adequate.

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciN/A

data presentationINADEQUATE

software identifiedADEQUATE

assumptions verifiedNOT REPORTED

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 90% conf

Statistical reporting is insufficient: only one test (ANOVA) is named, no post-hoc tests, no exact p-values, no effect sizes, and the number of replicates is not stated for cellular experiments.

Evidence

“Significant variations between groups were estimated using one-way ANOVA analysis.”

Statistical analysis

absence[Results, entire section]

No exact p-values are reported.

absence[Methods, MTT and subsequent sections]

Number of replicates for cellular experiments not stated.

WARNReviewer 2· 85% conf

Statistical methods are named but assumptions are not verified, exact p-values are not reported, effect sizes are absent, and data presentation is incomplete (no individual points).

Evidence

“Significant variations between groups were estimated using one-way ANOVA analysis.”

Statistical analysis

absence[Methods, 'Statistical Analysis']

Assumptions are not verified.

“The error bars represent standard deviation.”

Figure 6

WARNReviewer 3· 70% conf

The statistical analysis is partially reported: tests are named (one-way ANOVA) and software is identified, but assumptions are not verified, exact p-values are not reported, effect sizes without confidence intervals, and data presentation lacks per-group n.

Evidence

“Data were examined using SPSS v. 15.0. Significant variations between groups were estimated using one-way ANOVA analysis. p ≤ 0.05 was considered significant.”

Statistical analysis

“The error bars represent standard deviation.”

Figure legends

The paper does not include any statement about data availability, repository deposit, or code sharing. All four sub-criteria are not reported, resulting in a fail.

Sub-criteria

code sharingNOT REPORTED

accession numbersNOT REPORTED

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 95% conf

No data availability statement, data deposit, accession numbers, or code sharing are provided.

Evidence

absence[Entire paper]

No data availability statement.

absence[Entire paper]

No code repository mentioned.

FAILReviewer 2· 95% conf

No data availability statement, no repository deposit, no accession numbers, and no code sharing. None of the applicable criteria are met.

Evidence

absence[Entire paper]

No data availability statement is present.

absence[Entire paper]

No repository deposit is mentioned.

FAILReviewer 3· 90% conf

No data availability statement, repository deposit, accession numbers, or code sharing is provided.

Evidence

absence[End of manuscript]

No data availability statement.

absence[Methods]

No code sharing.

Methods for extraction, niosome preparation, and cell assays are described but lack details such as primer sequences for RT-PCR and exact number of replicates. No reporting guideline (ARRIVE, CONSORT) is referenced. All outcomes appear to be reported, and conclusions are proportional to the in vitro data. A conflicts of interest statement is present, but funding sources are not mentioned.

Sub-criteria

funding coiINADEQUATE

trial registrationN/A

reporting guidelineNOT REPORTED

methods completenessINADEQUATE

all outcomes reportedADEQUATE

limitations discussedINADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

Methods are partially described, but missing critical details (e.g., primer sequences, replication numbers), and no reporting guideline is referenced, though conclusions are proportional to the evidence.

Evidence

absence[Methods, RT-PCR Assay]

Primer sequences for RT-PCR not provided.

absence[Methods, entire section]

No reporting guideline referenced.

“The authors declare that they have no conflicts of interest for this work.”

End of paper, Disclosure

WARNReviewer 2· 85% conf

Methods are generally complete, all outcomes are reported, and conclusions are proportional, but no reporting guideline is referenced, limitations are superficially discussed, and funding is not disclosed.

Evidence

“Powdered peels were macerated with 20% methanol for 7 days in a dark place to avoid degradation by the effect of light.”

Methods

“future studies are required to use human skin and in vivo swine skin model of UV-mediated skin damage and aging to define the efficacy of punicalagin niosomes in skin aging.”

Discussion

absence[Compliance with Ethical Standards]

Funding sources are not disclosed.

PASSReviewer 3· 80% conf

Most aspects of reporting are adequate: all outcomes are reported, limitations are discussed, and conclusions are proportional. However, methods completeness and funding disclosure are lacking.

Evidence

Discussion

absence[End of manuscript]

No funding statement.

Broken references and links

2 findings · worst high

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Cites retracted workRecomputed
References not resolvable to a published paperRecomputed

Checked 48 references by DOI: 36 verified — 1 retracted, 1 DOI unresolved, 9 no DOI (shown, not verified), 1 lookup failed.

Copyediting

1 finding · worst low

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

12 copyedit issues flagged (1 major): mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work has significant methodological and reporting gaps that a reader should weigh carefully. The internal contradictions in the niosome size data and the TERT assay results warrant a correction or independent re-analysis. The presence of a retracted citation is a serious integrity concern.

1.
HIGHrigor
Address the internal contradiction in the TERT assay: the data show that punicalagin-treated UV-exposed cells (s.R) have 31.19% telomere shortening versus 14.22% for UV-only cells (cR), contradicting the claim that punicalagin protects against telomere shortening. Either provide a corrected analysis or remove the claim.
This is a direct contradiction between the presented data and the stated conclusion, which undermines the core finding of the paper.
2.
HIGHrigor
Remove or replace the retracted reference: 'Formulation, and evaluation of a topical niosomal gel containing a combination of benzoyl peroxide and tretinoin for antiacne activity' (DOI 10.2147/ijn.s70449).
Citing a retracted paper is a serious integrity violation; the authors must identify a valid replacement or remove the citation.
3.
HIGHrigor
Verify the reference not found in any registry: 'In vitro evaluation of antioxidant potential of isolated compounds and various extracts of peel of Punica granatum L.' (DOI 10.4103/pr.pr_36_17). Provide the correct citation or remove it.
A reference that cannot be located in Crossref/OpenAlex may be fabricated; the authors must confirm its existence and correct the bibliographic details.
4.
HIGHreporting
Add a data availability statement specifying where the raw data (e.g., cell viability, gene expression, flow cytometry) can be accessed, or state that they are available from the corresponding author upon reasonable request.
Without any data availability statement, the reproducibility of the findings cannot be assessed.
5.
HIGHrigor
Harmonize the reported niosome size ranges: Results state 135-200 nm for free niosomes, while Discussion states 180-220 nm. Correct the discrepancy.
This is an internal contradiction that could affect the interpretation of the formulation's properties.
6.
HIGHreporting
Report exact p-values and effect sizes with confidence intervals for all statistical comparisons, and specify the post-hoc test used after ANOVA.
Threshold-only p-values and lack of effect sizes are insufficient for a reader to assess the strength of the evidence.
7.
HIGHrigor
Provide cell line authentication (e.g., STR profiling) and mycoplasma testing results, or explicitly state that these were not performed as a limitation.
Without authentication and mycoplasma testing, the identity and quality of the cell line are uncertain, affecting reproducibility.
8.
HIGHreporting
Temper the claim that 'Punicalagin is promising as a natural antioxidant to protect human skin from aging' to reflect the in vitro nature of the evidence, and add a caution about the need for in vivo validation.
The current wording implies clinical applicability, which is not supported by the data.
9.
HIGHreporting
Disclose funding sources and grant numbers, even if the study was unfunded, in a separate section.
Funding transparency is a standard reporting requirement, and its absence is a gap.
10.
MEDIUMreporting
Provide the primer sequences for all RT-PCR genes (MMP3, Col1A1, Timp3, beta-actin) in the Methods section.
Without primer sequences, the RT-PCR assay cannot be reproduced.
11.
MEDIUMreporting
State the number of biological replicates (independent experiments) for each cell assay and distinguish them from technical replicates.
This is essential for assessing the statistical reliability of the results.
12.
MEDIUMcopyedit
Correct the unit 'Mm' to 'mM' throughout the manuscript (Methods, 'Effect of H2O2 and Punicalagin on HFB4') and add a space before the unit.
Inconsistent or incorrect unit notation is a readability issue that could cause confusion.

Full text (30,058 chars)Analyzed: Aug 5, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation

Mohamad EA, Aly AA, Khalaf AA, Ahmed MI, Kamel RM, Abdelnaby SM, Abdelzaher YH, Sedrak MG, Mousa SA.

Read full text (PMC)

Journal

DOI

10.2147/dddt.s316247

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/245ce65c-8e4a-4f57-a343-2b9b2822d30d" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/245ce65c-8e4a-4f57-a343-2b9b2822d30d/badge" alt="Kaimen Rigor review — 1★ (Critical), 0 critical, 9 high issues for “Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

c4730f21983ec5e99b4f2046116b612097bc6ac8407175f8ad0209ae9847025a

Verify via API

Issued Aug 5, 2026Engine 7.15.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×5−2.5★
ClaimsUnsupported claim (uncorroborated)−0.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design not met−0.5★
ReportingKey resources not met−0.5★
ReportingData & code availability not met−0.5★
ReportingStatistical analysis partially met−0.25★
ReportingReporting transparency partially met−0.25★
CitationsRetracted reference cited−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: moderateReviewer agreement: moderateEngine: 7.15.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.
No data or code availability links were detected to verify.

Biggest issues

01Conclusion not supported by the paper’s own evidence
highOverreachreviewer-assessedFull detail
Punicalagin increased human TERT concentration in skin cells.
telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s + H2O2 samples by only 31.19% and 6.5%, respectively
Resultsreviewer’s wording
02Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim rests on in vitro cell-based biomarkers (gene expression changes in MMP3, Col1A1, Timp3, TERT concentration, cell cycle arrest, and collagen level). The paper does not demonstrate target engagement at the tested dose (no PK/PD or dose–exposure relationship for the cellular effect) and does not cite validated evidence linking these surrogates to a clinical outcome in skin aging.
“Punicalagin succeeded in reducing the growth arrest of HFB4 cells, activated production of the Col1A1 and Timp3 genes, maintained collagen level, and lowered MMP3. Punicalagin increased human TERT concentration in skin cells.”
03Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect sizes (e.g., percentage telomere shortening: 64.20% vs 31.19% for H2O2, 14.22% vs 6.5% for UV) are presented without any anchor to a clinically or biologically meaningful threshold. No minimal clinically important difference or reference to physiological relevance is provided.
“telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s+H2O2 samples by only 31.19% and 6.5%”
04Study design lacks key rigor safeguards
highDisclosurereviewer-assessedFull detail
The study design lacks essential rigor elements: no randomization, blinding, power analysis, proper replication, or outlier handling. Only basic controls are present.
05Key resources not identified
highDisclosurereviewer-assessedFull detail
Key resources are poorly identified: cell line authentication and mycoplasma testing are absent, and most reagents lack catalog numbers. Only statistical software is adequately identified.
“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt”
Methods
06Data and code not shared
highDisclosurereviewer-assessedFull detail
No data availability statement, data deposit, accession numbers, or code sharing are provided.

6 further findings of this severity or below — every one is in the sections below, filed under its error type.

Findings by category

Numerical inconsistencies

1 finding · worst medium

Internal contradictions in the reported numbersAssessed

Overstated conclusions

5 findings · worst high

Conclusions not supported by the paper’s own evidenceAssessed
Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst medium

Methods and results do not matchAssessed

5 integrity concerns flagged (1 high).

Reporting gaps

5 findings · worst high

Data and code not sharedAssessed
Key resources not identifiedAssessed
Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Study design lacks key rigor safeguardsAssessed
Reporting/transparency gapsAssessed

Eight Dimensions2 pass · 2 warn · 3 fail

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedNOT REPORTED

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

The paper adequately cites prior work and establishes a logical rationale, but limitations of the study are only briefly mentioned.

Evidence

paraphrase[Introduction, paragraphs 1-6]

“Paraphrase: The introduction cites multiple references on skin aging, ROS, UV, pomegranate composition, and niosomes.”

“In this study, we extracted punicalagin from pomegranate peel and then encapsulated it in niosomes to treat the HFB4 cell line as an anti-aging agent.”

Introduction

Discussion

PASSReviewer 2· 90% conf

The paper adequately cites prior research on skin aging, ROS, and pomegranate compounds, and provides a logical rationale linking punicalagin's antioxidant properties to anti-aging effects.

Evidence

paraphrase[Introduction, paragraph 7]

“Previous studies showed that treating human skin fibroblasts with 0–500 µM H2O2 decreased the viability of cells in a concentration-dependent manner.”

“The natural antioxidants from plant secondary metabolites can protect human skin from photoaging.”

Introduction ¶9

absence[Introduction]

Limitations of prior research are not discussed.

WARNReviewer 3· 70% conf

Evidence

paraphrase[Introduction, paragraphs 1-5]

“The introduction cites multiple references on skin aging, ROS, collagen, MMPs, TIMPs, telomerase, antioxidants, and pomegranate.”

absence[Introduction]

Strengths and weaknesses of prior work are not acknowledged.

absence[Introduction]

Limitations of prior research are not addressed.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsNOT REPORTED

outlier handlingNOT REPORTED

randomization unitNOT REPORTED

inclusion exclusionNOT REPORTED

randomization methodNOT REPORTED

replicate distinctionNOT REPORTED

independent replicationNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 90% conf

The study lacks essential design elements such as randomization, blinding, power analysis, and replication, with only controls adequately reported.

Evidence

paraphrase[Methods, Effect of H2O2 and Punicalagin on HFB4]

absence[Methods, entire section]

No randomization or blinding is mentioned.

absence[Methods, Statistical Analysis]

No power analysis or sample size calculation is reported.

FAILReviewer 2· 95% conf

The study design lacks essential rigor elements: no randomization, blinding, power analysis, proper replication, or outlier handling. Only basic controls are present.

Evidence

paraphrase[Methods, 'Effect of H2O2 and Punicalagin on HFB4']

“untreated cells (CC), cells treated with concentration (0.11 mM) of H2O2 (H2O2/HFB4), and cells treated with punicalagin (0.27 Mm) in addition to hydrogen peroxide (0.11 mM) (s + H2O2).”

absence[Methods]

No randomization or blinding is mentioned.

absence[Methods]

No a priori power analysis is reported.

FAILReviewer 3· 80% conf

Evidence

absence[Methods]

No power analysis reported.

absence[Methods, Cell Culture and Assays]

Biological vs technical replicates not distinguished.

paraphrase[Methods, Effect of H2O2 and Punicalagin on HFB4]

Sub-criteria

demographicsN/A

sex reportedN/A

sex justifiedN/A

age weight healthN/A

housing conditionsN/A

species strain sourceINADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The study uses a commercially available human cell line, and the reporting of biological variables is not applicable since the criteria are designed for animal or human subjects.

Evidence

paraphrase[Methods, Materials]

“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt.”

absence[Methods, Materials]

No RRID or authentication details are provided.

N/AReviewer 2· 90% conf

The study uses a human fibroblast cell line (HFB4), not animals or human subjects, so biological variables such as sex, age, and housing conditions are not applicable.

Evidence

“HFB4 (human dermal fibroblast) cell lines were preserved as a culture of monolayer in Dulbecco′s Modified Eagle′s Medium”

Methods

PASSReviewer 3· 90% conf

The only applicable biological variable, the cell line species/strain, is adequately reported. Other variables are not applicable for an in vitro cell line study.

Evidence

paraphrase[Methods, Materials]

“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt.”

Sub-criteria

iacuc statementN/A

informed consentN/A

irb ethics statementN/A

regulatory complianceN/A

Per reviewer (3) — the votes behind the verdict

N/AReviewer 1· 95% conf

The study uses a commercially available cell line and does not involve human subjects or animals, so ethics approval is not required.

Evidence

“The study was conducted in accordance with the international guidelines.”

End of paper, Compliance with Ethical S…

N/AReviewer 2· 95% conf

The study involves only a commercial cell line and no human or animal subjects, so ethical approval is not required.

Evidence

“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt”

Methods

N/AReviewer 3· 95% conf

The study uses a commercially available human cell line and does not involve animal or human subjects, so ethics approval is not required.

Evidence

“The study was conducted in accordance with the international guidelines.”

Compliance with Ethical Standards

Sub-criteria

mycoplasma testingNOT REPORTED

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationNOT REPORTED

software tools identifiedADEQUATE

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 85% conf

Key resources such as cell line authentication, mycoplasma testing, and full reagent catalog numbers are not reported, while software is identified but inadequately.

Evidence

absence[Methods, Materials]

Cell line authentication not reported.

absence[Methods, all sections]

Mycoplasma testing not reported.

“Methanol, ethanol, and Tween 80 were supplied from Sigma-Aldrich Co. (Schnelldorf, Germany).”

Methods

FAILReviewer 2· 90% conf

Key resources are poorly identified: cell line authentication and mycoplasma testing are absent, and most reagents lack catalog numbers. Only statistical software is adequately identified.

Evidence

“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt”

Methods

absence[Methods]

Mycoplasma testing is not reported.

“Fetal bovine serum (FBS) was purchased from Invitrogen Corp. (Carlsbad, CA, USA). Penicillin-streptomycin, trypsin, EDTA, and Hank’s buffer were purchased from Gibco, New York, NY, USA.”

Methods

FAILReviewer 3· 80% conf

Key resources are inadequately identified: cell line authentication, mycoplasma testing, and reagent catalog numbers are not reported. Only software is adequately identified.

Evidence

absence[Methods, Materials]

Cell line authentication not reported.

absence[Methods]

Mycoplasma testing not reported.

“Tween 80 were supplied from Sigma-Aldrich Co. (Schnelldorf, Germany).”

Methods

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciN/A

data presentationINADEQUATE

software identifiedADEQUATE

assumptions verifiedNOT REPORTED

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 90% conf

Statistical reporting is insufficient: only one test (ANOVA) is named, no post-hoc tests, no exact p-values, no effect sizes, and the number of replicates is not stated for cellular experiments.

Evidence

“Significant variations between groups were estimated using one-way ANOVA analysis.”

Statistical analysis

absence[Results, entire section]

No exact p-values are reported.

absence[Methods, MTT and subsequent sections]

Number of replicates for cellular experiments not stated.

WARNReviewer 2· 85% conf

Statistical methods are named but assumptions are not verified, exact p-values are not reported, effect sizes are absent, and data presentation is incomplete (no individual points).

Evidence

“Significant variations between groups were estimated using one-way ANOVA analysis.”

Statistical analysis

absence[Methods, 'Statistical Analysis']

Assumptions are not verified.

“The error bars represent standard deviation.”

Figure 6

WARNReviewer 3· 70% conf

Evidence

“Data were examined using SPSS v. 15.0. Significant variations between groups were estimated using one-way ANOVA analysis. p ≤ 0.05 was considered significant.”

Statistical analysis

“The error bars represent standard deviation.”

Figure legends

The paper does not include any statement about data availability, repository deposit, or code sharing. All four sub-criteria are not reported, resulting in a fail.

Sub-criteria

code sharingNOT REPORTED

accession numbersNOT REPORTED

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (3) — the votes behind the verdict

FAILReviewer 1· 95% conf

No data availability statement, data deposit, accession numbers, or code sharing are provided.

Evidence

absence[Entire paper]

No data availability statement.

absence[Entire paper]

No code repository mentioned.

FAILReviewer 2· 95% conf

No data availability statement, no repository deposit, no accession numbers, and no code sharing. None of the applicable criteria are met.

Evidence

absence[Entire paper]

No data availability statement is present.

absence[Entire paper]

No repository deposit is mentioned.

FAILReviewer 3· 90% conf

No data availability statement, repository deposit, accession numbers, or code sharing is provided.

Evidence

absence[End of manuscript]

No data availability statement.

absence[Methods]

No code sharing.

Sub-criteria

funding coiINADEQUATE

trial registrationN/A

reporting guidelineNOT REPORTED

methods completenessINADEQUATE

all outcomes reportedADEQUATE

limitations discussedINADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

Evidence

absence[Methods, RT-PCR Assay]

Primer sequences for RT-PCR not provided.

absence[Methods, entire section]

No reporting guideline referenced.

“The authors declare that they have no conflicts of interest for this work.”

End of paper, Disclosure

WARNReviewer 2· 85% conf

Evidence

“Powdered peels were macerated with 20% methanol for 7 days in a dark place to avoid degradation by the effect of light.”

Methods

“future studies are required to use human skin and in vivo swine skin model of UV-mediated skin damage and aging to define the efficacy of punicalagin niosomes in skin aging.”

Discussion

absence[Compliance with Ethical Standards]

Funding sources are not disclosed.

PASSReviewer 3· 80% conf

Most aspects of reporting are adequate: all outcomes are reported, limitations are discussed, and conclusions are proportional. However, methods completeness and funding disclosure are lacking.

Evidence

Discussion

absence[End of manuscript]

No funding statement.

Broken references and links

2 findings · worst high

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Cites retracted workRecomputed
References not resolvable to a published paperRecomputed

Checked 48 references by DOI: 36 verified — 1 retracted, 1 DOI unresolved, 9 no DOI (shown, not verified), 1 lookup failed.

Copyediting

1 finding · worst low

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

12 copyedit issues flagged (1 major): mostly typo, consistency, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHrigor
Address the internal contradiction in the TERT assay: the data show that punicalagin-treated UV-exposed cells (s.R) have 31.19% telomere shortening versus 14.22% for UV-only cells (cR), contradicting the claim that punicalagin protects against telomere shortening. Either provide a corrected analysis or remove the claim.
This is a direct contradiction between the presented data and the stated conclusion, which undermines the core finding of the paper.
2.
HIGHrigor
Remove or replace the retracted reference: 'Formulation, and evaluation of a topical niosomal gel containing a combination of benzoyl peroxide and tretinoin for antiacne activity' (DOI 10.2147/ijn.s70449).
Citing a retracted paper is a serious integrity violation; the authors must identify a valid replacement or remove the citation.
3.
HIGHrigor
Verify the reference not found in any registry: 'In vitro evaluation of antioxidant potential of isolated compounds and various extracts of peel of Punica granatum L.' (DOI 10.4103/pr.pr_36_17). Provide the correct citation or remove it.
A reference that cannot be located in Crossref/OpenAlex may be fabricated; the authors must confirm its existence and correct the bibliographic details.
4.
HIGHreporting
Add a data availability statement specifying where the raw data (e.g., cell viability, gene expression, flow cytometry) can be accessed, or state that they are available from the corresponding author upon reasonable request.
Without any data availability statement, the reproducibility of the findings cannot be assessed.
5.
HIGHrigor
Harmonize the reported niosome size ranges: Results state 135-200 nm for free niosomes, while Discussion states 180-220 nm. Correct the discrepancy.
This is an internal contradiction that could affect the interpretation of the formulation's properties.
6.
HIGHreporting
Report exact p-values and effect sizes with confidence intervals for all statistical comparisons, and specify the post-hoc test used after ANOVA.
Threshold-only p-values and lack of effect sizes are insufficient for a reader to assess the strength of the evidence.
7.
HIGHrigor
Provide cell line authentication (e.g., STR profiling) and mycoplasma testing results, or explicitly state that these were not performed as a limitation.
Without authentication and mycoplasma testing, the identity and quality of the cell line are uncertain, affecting reproducibility.
8.
HIGHreporting
Temper the claim that 'Punicalagin is promising as a natural antioxidant to protect human skin from aging' to reflect the in vitro nature of the evidence, and add a caution about the need for in vivo validation.
The current wording implies clinical applicability, which is not supported by the data.
9.
HIGHreporting
Disclose funding sources and grant numbers, even if the study was unfunded, in a separate section.
Funding transparency is a standard reporting requirement, and its absence is a gap.
10.
MEDIUMreporting
Provide the primer sequences for all RT-PCR genes (MMP3, Col1A1, Timp3, beta-actin) in the Methods section.
Without primer sequences, the RT-PCR assay cannot be reproduced.
11.
MEDIUMreporting
State the number of biological replicates (independent experiments) for each cell assay and distinguish them from technical replicates.
This is essential for assessing the statistical reliability of the results.
12.
MEDIUMcopyedit
Correct the unit 'Mm' to 'mM' throughout the manuscript (Methods, 'Effect of H2O2 and Punicalagin on HFB4') and add a space before the unit.
Inconsistent or incorrect unit notation is a readability issue that could cause confusion.

Full text (30,058 chars)Analyzed: Aug 5, 2026